{"id":177650,"date":"2026-01-24T04:13:29","date_gmt":"2026-01-24T09:13:29","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=177650"},"modified":"2026-01-26T04:21:57","modified_gmt":"2026-01-26T09:21:57","slug":"onesource-specialty-pharma-ltd-operational-scale-expands-amid-near-term-earnings-volatility","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/onesource-specialty-pharma-ltd-operational-scale-expands-amid-near-term-earnings-volatility\/","title":{"rendered":"OneSource Specialty Pharma Ltd operational scale expands amid near-term earnings volatility"},"content":{"rendered":"\n

OneSource Specialty Pharma Ltd (BSE: 544292 \/ NSE: ONESOURCE) has emerged as a multi-modality contract development and manufacturing organisation (CDMO) following the integration of biologics, drug-device combinations, sterile injectables, and oral technologies businesses. While near-term financial performance in Q3 FY26 was affected by regulatory approval delays and revenue deferrals, disclosures indicate continued expansion in capacity, customer pipeline, and long-term growth ambitions supported by structural demand in the global CDMO market.<\/p>\n\n\n\n

Business Profile and Strategic Positioning<\/h2>\n\n\n\n

OneSource operates as a pure-play specialty pharmaceutical CDMO with five manufacturing facilities and capabilities spanning biologics, drug-device combinations, sterile injectables, and soft gelatin capsules. The company serves a global customer base across pharmaceutical and biotechnology companies and employs more than 1,300 professionals.<\/p>\n\n\n\n

The formation of OneSource through the consolidation of multiple specialty pharma assets has created an integrated platform with end-to-end development and manufacturing capabilities. Management has positioned the company as a multi-modality CDMO with scalability across therapeutic modalities and delivery formats.<\/p>\n\n\n\n

Financial and Operating Performance<\/h2>\n\n\n\n

For Q3 FY26, OneSource reported revenue of \u20b92,903 million, compared with \u20b93,758 million in Q2 FY26 and \u20b93,926 million in Q3 FY25. EBITDA declined to \u20b9173 million, with EBITDA margin at 6%, compared with 28% in the preceding quarter and 36% in the same quarter last year. The company reported an adjusted loss at the profit-after-tax level, reflecting lower revenue and a largely fixed cost base.<\/p>\n\n\n\n

The company attributed the quarterly decline primarily to delayed customer approvals in Canada for semaglutide, which led to deferred revenue recognition.<\/p>\n\n\n\n

At the operational level, OneSource reported continued expansion in its biologics pipeline, including onboarding of a global biosimilar customer and an increase in biologics projects at various stages of development. The company also reported ongoing momentum in customer engagements, repeat business, and request-for-proposal activity.<\/p>\n\n\n\n

Structural Growth Drivers<\/h2>\n\n\n\n

Disclosures highlight multiple long-term drivers supporting OneSource\u2019s business model, including rising demand for complex biologics, patent expiries of blockbuster molecules, supply chain diversification by global pharmaceutical companies, and increasing preference for integrated CDMO partners.<\/p>\n\n\n\n

The company has outlined a medium-term ambition to reach $400 million in organic revenue and $500 million including a proposed acquisition by FY28, with an EBITDA margin outlook of around 40%, subject to approvals.<\/p>\n\n\n\n

Governance, Capital and Execution Framework<\/h2>\n\n\n\n

OneSource\u2019s governance structure includes an independent board with global pharmaceutical and financial expertise. The company has committed to significant capital expenditure to expand capacity in drug-device combinations and biologics, supported by a mix of equity, internal accruals, and borrowings.<\/p>\n\n\n\n

Management disclosures emphasise execution, regulatory compliance, capacity expansion, and customer diversification as key operational priorities in the near to medium term.<\/p>\n\n\n\n

Based on disclosures, OneSource exhibits a combination of near-term earnings volatility and longer-term structural expansion, with operational scale, customer pipeline depth, and capacity investments forming the core drivers of its business trajectory.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

OneSource Specialty Pharma Ltd (BSE: 544292 \/ NSE: ONESOURCE) has emerged as a multi-modality contract development and manufacturing organisation (CDMO) following the integration of biologics, drug-device combinations, sterile injectables, and oral technologies businesses. While near-term financial performance in Q3 FY26 was affected by regulatory approval delays and revenue deferrals, disclosures indicate continued expansion in capacity, […]<\/p>\n","protected":false},"author":2390,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392,1941,5747],"tags":[14743,14741,14746,14744,14580,14496,14747,14742,14745,14738,14737,14736,14739,14559,14740],"class_list":["post-177650","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings","category-stock-analysis","category-healthcare-stocks","tag-biologics-manufacturing","tag-bse-544292","tag-cdmo-sector-india","tag-contract-manufacturing-pharma","tag-corporate-earnings-india","tag-indian-stock-market","tag-nse-onesource","tag-onesource-earnings","tag-onesource-q3-fy26","tag-onesource-results","tag-onesource-specialty-pharma","tag-onesource-specialty-pharma-ltd","tag-onesource-stock","tag-quarterly-results-india","tag-specialty-pharma-india"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":177629,"url":"https:\/\/alphastreet.com\/india\/onesource-specialty-pharma-ltd-reports-q3-fy26-revenue-of-%e2%82%b92-9-billion-ebitda-declines-amid-approval-delays\/","url_meta":{"origin":177650,"position":0},"title":"OneSource Specialty Pharma Ltd reports Q3 FY26 revenue of \u20b92.9 billion, EBITDA declines amid approval delays","author":"Staff Correspondent","date":"January 24, 2026","format":false,"excerpt":"OneSource Specialty Pharma Ltd (BSE: 544292 \/ NSE: ONESOURCE) reported consolidated revenue of \u20b92.9 billion for the quarter ended December 31, 2025, a decline of 26% year-on-year, according to its Q3 FY26 earnings release. EBITDA stood at \u20b9173 million, down 88% from the corresponding quarter last year, while adjusted profit\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":175850,"url":"https:\/\/alphastreet.com\/india\/strides-pharma-science-limited-star-q2-2025-earnings-call-transcript\/","url_meta":{"origin":177650,"position":1},"title":"Strides Pharma Science Limited (STAR) Q2 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Strides Pharma Science Limited (NSE: STAR) Q2 2025 Earnings Call dated Oct. 24, 2024 Corporate Participants: Abhishek Singhal \u2014 Investor Relations Arun Kumar \u2014 Executive Chairperson Analysts: Rupesh Tatiya \u2014 Analyst Naman Bhansali \u2014 Analyst Nitin Agarwal \u2014 Analyst Abdulkader Puranwala \u2014 Analyst Aman Vij \u2014 Analyst Ritesh Oswal \u2014\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":174424,"url":"https:\/\/alphastreet.com\/india\/onesource-specialty-pharma-ltd-onesource-q3-2025-earnings-call-transcript\/","url_meta":{"origin":177650,"position":2},"title":"Onesource Specialty Pharma Ltd (ONESOURCE) Q3 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Onesource Specialty Pharma Ltd (NSE: ONESOURCE) Q3 2025 Earnings Call dated Jan. 29, 2025 Corporate Participants: Unidentified Speaker Arun Kumar \u2014 Founder and Non-Executive Director Neeraj Sharma \u2014 Chief Executive Officer and Managing Director Anurag Bhagania \u2014 Chief Financial Officer Analysts: Nitin Agarwal \u2014 Anallyst Amey Chalke \u2014 Analyst Kunal\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":177620,"url":"https:\/\/alphastreet.com\/india\/onesource-specialty-pharma-ltd-onesource-q3-2026-earnings-call-transcript\/","url_meta":{"origin":177650,"position":3},"title":"Onesource Specialty Pharma Ltd (ONESOURCE) Q3 2026 Earnings Call Transcript","author":"News desk","date":"January 26, 2026","format":false,"excerpt":"Onesource Specialty Pharma Ltd (NSE: ONESOURCE) Q3 2026 Earnings Call dated Jan. 24, 2026 Corporate Participants: Arun Kumar \u2014 Founder and Non-Executive Director Neeraj Sharma \u2014 Chief Executive Officer and Managing Director Anurag Bhagania \u2014 Chief Financial Officer Abhishek Singhal \u2014 Company Secretary Analysts: Unidentified Participant Abdulkader Puranwala \u2014 Analyst\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":174423,"url":"https:\/\/alphastreet.com\/india\/onesource-specialty-pharma-ltd-onesource-q4-2025-earnings-call-transcript\/","url_meta":{"origin":177650,"position":4},"title":"Onesource Specialty Pharma Ltd (ONESOURCE) Q4 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Onesource Specialty Pharma Ltd (NSE: ONESOURCE) Q4 2025 Earnings Call dated May. 06, 2025 Corporate Participants: Unidentified Speaker Arun Kumar \u2014 Founder and Non-Executive Director Neeraj Sharma \u2014 Chief Executive Officer and Managing Director Anurag Bhagania \u2014 Chief Financial Officer Analysts: Unidentified Participant Aman \u2014 Analyst Madhav Marda \u2014 Analyst\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":174422,"url":"https:\/\/alphastreet.com\/india\/onesource-specialty-pharma-ltd-onesource-q1-2026-earnings-call-transcript\/","url_meta":{"origin":177650,"position":5},"title":"Onesource Specialty Pharma Ltd (ONESOURCE) Q1 2026 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Onesource Specialty Pharma Ltd (NSE: ONESOURCE) Q1 2026 Earnings Call dated Aug. 05, 2025 Corporate Participants: Unidentified Speaker Arun Kumar \u2014 Founder and Non-Executive Director Neeraj Sharma \u2014 Managing Director and Chief Executive Officer Anurag Bhagania \u2014 Chief Financial Officer Analysts: Unidentified Participant Abhishek Singhal \u2014 Analyst Anand Mundra \u2014\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2390"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=177650"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177650\/revisions"}],"predecessor-version":[{"id":177653,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177650\/revisions\/177653"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=177650"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=177650"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=177650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}